基石药业-B(02616)下跌2.69%，报9.03元/股

Group 1 - The core viewpoint of the article highlights the recent stock performance of Basilea Pharmaceutica Ltd. (02616), which experienced a decline of 2.69% to 9.03 HKD per share, with a trading volume of 9.65 billion HKD [1] - Basilea is a biopharmaceutical company focused on the research and development of anti-tumor drugs, having successfully launched four innovative drugs and received approval for 16 new drug applications [1] - The company currently has 16 potential innovative drugs and operates across the entire chain from research and development to commercialization [1] Group 2 - As of the mid-year report in 2025, Basilea reported total revenue of 49.451 million HKD and a net loss of 270 million HKD [2]